Trials / Recruiting
RecruitingNCT06612970
A Study to Evaluate Single-dose of HB0056 in Healthy Adult Participants
A Phase 1a, Randomized, Double-blind, Placebo-controlled, Single Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HB0056 in Adult Healthy Subjects.
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The aim of this study is to investigate the safety and tolerability of HB0056 in healthy subjects following single-dose.
Detailed description
This is a single-dose escalation study of HB0056 to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of HB0056.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HB0056 | HB0056 Injection |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2024-11-18
- Primary completion
- 2025-06-13
- Completion
- 2025-10-01
- First posted
- 2024-09-25
- Last updated
- 2025-09-08
Locations
1 site across 1 country: New Zealand
Source: ClinicalTrials.gov record NCT06612970. Inclusion in this directory is not an endorsement.